EyeCool Therapeutics reaches coding milestone for ocular cooling procedure

EyeCool Therapeutics has reached a new milestone in the development of its precision ocular cooling technology, following the publication of a new Category III Current Procedural Terminology code by the American Medical Association. The newly published code, 1115T, covers a procedure involving transconjunctival cooling directed towards the long ciliary nerves for ocular pain. The code was accepted by the AMA's CPT Editorial Panel during its September 2026 meeting and is scheduled to take effect on 1 January 2027. For EyeCool, the publication provides a standardised way to identify and track the procedure as clinical development continues. Category III CPT codes are used for emerging medical procedures and technologies, helping collect information about their use while clinical evidence develops. The company is developing ETX 4143, an investigational in office device designed to deliver controlled, localised cooling to the surface of the eye. EyeCool is evaluating the technology as a potential treatment for chronic ocular surface pain, a condition that can affect patients over an extended period and for which the company is pursuing a new treatment approach. Ruben F. Salinas, President and Chief Executive Officer of EyeCool Therapeutics, said the publication of a dedicated code represents an important step in the development of ocular cooling as a potential therapeutic category. He said the code will provide a standardised mechanism for identifying and tracking the procedure once it becomes effective. The coding development comes as EyeCool continues to build its clinical and scientific evidence base for precision ocular cooling. The company has reported published clinical studies involving ETX 4143 and is preparing for the next stage of its clinical development programme in the United States. The new CPT code does not mean that the procedure is automatically covered or reimbursed by health insurers. Category III codes do not establish insurance coverage or payment, and their inclusion in the CPT code set does not represent endorsement by the American Medical Association. The code also cannot be reported before its effective date of 1 January 2027. The publication of the code does not represent approval or clearance from the US Food and Drug Administration for EyeCool's investigational device. EyeCool Therapeutics is a clinical stage medical device company developing precision ocular cooling as a potential treatment approach for chronic ocular surface pain. Its lead investigational device, ETX 4143, is being evaluated in clinical development as the company works towards further studies in the United States.

See All Episodes